VHH Bi-specific Antibodies for Next-Generation Therapeutics
Compact, engineerable binding domains for complex multi-target formats
VHH single-domain antibodies enable flexible bi-specific and multi-specific architectures that can otherwise be difficult to engineer using conventional IgG-based formats. This is largely due to the simplicity of the single-domain format, which avoids heavy/light chain pairing issues and makes modular assembly more straightforward.
Antibody formatting can be challenging
Antibody engineering relies strongly on modular architectures to achieve desired mode of action (MoA) such as conditional agonists/antagonists and specific T cell engagers. However, IgG-based formats, including scFvs and Fc-fused constructs, introduce significant design and development challenges such as chain mispairing, steric hinderance, restricted binding, and increased manufacturing complexity.
These limitations become more pronounced as constructs increase in complexity, as seen in bi-specific and tri-specific antibodies where structural constraints can impact feasibility, stability and translational success.
VHH single-domain antibodies offer a fundamentally different design space for addressing these challenges.
Diagram 1 – Conventional IgG vs VHH bi-specific architectures
How It Works (mechanisms)
1. VHHs as compact, single-domain binders
VHHs are one of the smallest naturally occurring antigen-binding antibody domains. Unlike conventional antibodies, they consist of a single variable domain and do not require heavy–light chain pairing.
This enables:
- Simplified molecular architecture
- Elimination of chain mispairing risks
- Access to epitopes that may be sterically restricted for larger antibodies
Their simplicity also offers more choice of potential expression hosts, unlocking new routes to lower cost of goods, as well as being an ideal choice for in vivo expression in cell and gene therapies.
Their intrinsic stability also makes them well suited to intensive engineering.
2. Enabling flexible bi-specific and multi-specific formats
Because VHHs can be genetically linked in a modular fashion, they support a wide range of architectures, including:
- Tandem VHH–VHH bi-specifics
- VHH–Fab or VHH–IgG hybrid formats
- Multi-specific chains incorporating additional functional domains
This flexibility allows geometry, spacing, and valency to be tuned to the biology of the target system rather than constrained by antibody format.
Whether you are starting your bi-specific build from scratch or have an existing molecule you want to ‘supercharge’. VHHs can provide a quick and straightforward solution.
Diagram 2 – VHH chaining and modular bispecific designs
3. Relevance to T-cell engagers and immune synapse formation
VHHs are particularly well suited to T-cell engager formats, where compact size and precise geometry can influence immune synapse formation and functional activity.
Compared to larger IgG-based formats, VHH-based T-cell engagers can:
- Reduce steric hindrance at the synapse
- Enable tighter spatial control between targets
- Facilitate compact, multi-specific architectures
Diagram 3 – T-cell engager geometry (IgG vs VHH-based)
Is your discovery strategy aligned with the final VHH antibody format?
Applications / Use Cases
VHH bi-specific antibodies are well suited to applications where compact size, modularity, and tuneable pharmacokinetics provide advantages over conventional antibody formats.
Representative use cases
- T-cell engagers requiring compact immune synapse formation
- Oncology therapeutics targeting multiple pathways or cell types
- Conditional or multi-specific biologics where modular design is essential
- Applications requiring tailored pharmacokinetics, from rapidly clearing imaging agents to half-life–extended therapeutic formats (e.g. via Fc fusion or albumin binding)
Key advantages of VHH in bi-specifics
Designed for complex antibody engineering
- Compact binding domains enable architectures that are difficult with conventional antibodies
- High stability supports extensive genetic fusion and optimisation
- Modular design allows integration with half-life extension, payload delivery or other functional domains
Discovery aligned to final format
Isogenica takes the intended bi-specific architecture into consideration during VHH discovery and can assess binder compatibility early, helping to identify candidates suitable for downstream engineering and development.
This helps reduce late-stage redesign and technical risk.
How can we help you?
At Isogenica, we have a track record of delivering clinical assets both through our own internal discovery programmes and through our collaborative partnerships with global pharmaceutical companies and world-leading research organisations.
For example, we have teamed up with Professor Martin Dyer’s lab at the University of Leicester, UK to develop bi-specific immunotherapies for blood cancers such as multiple myeloma and diffuse large B cell lymphoma.
Talk to our expert team to find out how VHHs can transform your biotherapeutic development.
Design your bi-specific antibody with VHHs
Speak to our scientists about VHH discovery strategies for complex bi-specific or multi-specific programmes.
FAQs
Can VHHs be used in bi-specific formats?
Yes. Their compact structure supports VHH–VHH and VHH–Fab multispecific designs.
Do you generate VHHs for T-cell engagers?
Yes. We deliver high-affinity binders with optional functional validation.
Why are VHHs particularly well suited to bi-specific and multi-specific designs?
Their small size, stability, and modularity enable precise geometry and valency control.
Isogenica’s
VHH in bi-specifics
RESOURCES
Nature webinar: VHH as building blocks for immune and tumour cell-targeting
VHH are fast becoming accepted as alternatives to standard antibody-based biotherapeutics. The recent approval of caplacizumab, and the emergence of numerous other examples of VHH-based antibodies in clinical trials, are spurring enthusiasm for this format.
From monoclonals to bi-specifics: Harnessing the transformative power of VHHs to supercharge IgG therapeutics
Since their discovery over thirty years ago, monoclonal antibodies (mAbs) based on Immunoglobulin G (IgG) have transformed the diagnosis and treatment of many diseases.
Explore the science behind our antibody discovery platforms
White Paper “Data-Driven Validation of Synthetic VHHs”
This white paper provides a data-driven validation of Isogenica’s synthetic VHH libraries, powered by Colibra® technology. Designed for biotech and pharmaceutical scientists, it demonstrates how these libraries enhance and accelerate drug discovery, particularly in oncology and immunotherapy. Download Extending half-lives of VHH antibodies
Because VHHs are small, they can be cleared quickly from the bloodstream. This can be a useful feature for some applications, but often a longer plasma half-life is desirable. DOWNLOADAdvantages of VHH in bi-specifics
To learn more about the application of VHHs in bi-specifics, we have condensed our expertise into a downloadable Application Note. DOWNLOADOptimizing CAR-T and T-cell antibody engagers: a role for VHH single domain antibodies
This whitepaper summarises the clinical and research landscape for CAR-T and T-cell engaging antibody therapies and show how single domain VHH antibodies can be applied to optimise the next generation of these important new therapeutic modalities. DOWNLOADIsogenica’s PD-L1 VHH as Functional Antagonists
PD-1 is an immune checkpoint protein expressed on the surface of multiple types of immune cells, including antigen-stimulated T-cells and tumour specific T-cells1. Interaction between PD-1 and its ligands (PD-L1 or PD-L2), is responsible for the regulation of T-cell activation, apoptosis, proliferation and cytokine production. DOWNLOADAnti-LRP5/6 VHH inhibits WNT pathway and prevents tumour growth
VHH are the variable domain of heavy chain only antibodies. They are small in size (~15 kD) and biophysically robust. With tunable half-lives, these antibodies are ideal for targeting inaccessible epitopes, achieving enhanced tissue penetration, multi-target binding and formatting for payload delivery… DOWNLOAD